Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Clark, Jeffrey W.
Weiss, Jared
Ou, Sai-Hong Ignatius
Camidge, D. Ross
Solomon, Benjamin J.
Otterson, Gregory A.
Villaruz, Liza C.
Riely, Gregory J.
Heist, Rebecca S.
Awad, Mark M.
Shapiro, Geoffrey I.
Satouchi, Miyako
Hida, Toyoaki
Hayashi, Hidetoshi http://orcid.org/0000-0001-8787-5587
Murphy, Danielle A.
Wang, Sherry C.
Li, Sherry
Usari, Tiziana
Wilner, Keith D.
Paik, Paul K.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748)
Article History
Received: 3 July 2019
Accepted: 24 November 2019
First Online: 13 January 2020
Competing interests
: A.D. reports receiving fees for consulting/advisory board roles at AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Genentech/Roche, Helsinn, Ignyta, Loxo/Lilly, Pfizer, TP Therapeutics, BergenBio, Exelixis, Tyra, Verastem, MORE Health, Abbvie, GlaxoSmithKlein, Teva, PharmaMar, Taiho, Merck, Puma, Merus and Takeda/Ariad/Millenium. J.W.C. has nothing to disclose. J.W. reports receiving fees for speaker or advisory board roles from AstraZeneca, Biodesix, BioMarck Pharmaceuticals, Clovis Oncology, Eli Lilly, EMD Serono, Genentech and Inivata, and that his institution has received grant/research support from AstraZeneca, Astellas, Celgene, Merck, Novartis and Pfizer. S.-H.I.O. reports receiving fees for serving on speaker bureaus for AstraZeneca, Genentech and Takeda, fees for speaker or advisory board roles from AstraZeneca, Foundation Medicine, Novartis, Pfizer, Roche/Genentech and Takeda, honoraria from ARIAD/Takeda, AstraZeneca, Foundation Medicine, Genentech/Roche, Novartis, Pfizer and Roche Pharma AG, and that his institution has received grant/research support from ARIAD, Astellas Pharma, AstraZeneca, AstraZeneca/MedImmune, Chugai Pharma, Clovis Oncology, GlaxoSmithKline, Ignyta, Peregrine Pharmaceuticals, Pfizer and Roche Pharma AG. D.R.C. reports that his institution has received grant/research support from Pfizer. B.J.S. reports receiving fees for speaker or advisory board roles for AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer and Roche/Genentech, honoraria from AstraZeneca and Bristol-Myers Squibb, that his institution has received grant/research support from Pfizer, that he has collected royalties and/or is an IP rights/patent holder with Veristrat (Biodesix), and that he has received other payment (travel, accommodations, expenses) from AstraZeneca, Bristol-Myers Squibb, Merck, Novartis and Roche. G.A.O. reports receiving fees for advisory board roles with Amgen, Genentech, Novartis, Pfizer and Takeda, and that his institution has received grant/research support from Astra Zeneca, BMS, Clovis, Genentech, Ignyta, Merck, Novartis and Pfizer. L.C.V. reports receiving fees for speaker or advisory board roles for Pfizer. G.J.R. reports receiving fees for speaker or advisory board roles from Genentech, and that his institution has received grant/research support from Ariad, GlaxoSmithKline, Infinity Pharmaceuticals, Millenium, Novartis, Pfizer and Roche/Genetech. R.S.H. reports receiving honoraria from Boehringer Ingelheim, and that her institution has received grant/research support from Abbvie, Agios, Celgene, Corvus, Daichii, Debiopharm, Genentech/Roche, Incyte, Millenium, Novartis and Peregrine. M.M.A. reports receiving fees for consulting/advisory board roles with Abbvie, ARIAD, AstraZeneca/MedImmune, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Foundation Medicine, Genentech, Merck, Nektar, Novartis, Pfizer and Syndax, and that his institution has received grant/research support from Bristol-Myers Squibb. G.I.S. reports receiving fees for speaker or advisory board roles from G1 Therapeutics, Lilly, Pfizer, Roche and Vertex Pharmaceuticals, and that his institution has received grant/research support from Pfizer and Lilly. M.S. reports receiving honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Merck, Novartis, Ono Pharmaceutical, Pfizer Japan and Taiho Pharmaceutical, and that his institution has received grant/research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Merck, Novartis, Ono Pharmaceutical, Pfizer Japan and Taiho Pharmaceutical. T.H. reports receiving fees for consulting/advisory board roles from Novartis, and receiving honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Chugai Pharmaceutical, Clovis Oncology, Eli Lilly, Nippon, Novartis, Ono Pharmaceutical, Pfizer and Taiho Pharmaceutical. H.H. reports receiving fees for consulting/advisory board roles from AstraZeneca, Boehringer Ingelheim, Chugai Pharma and Lilly. D.A.M. reports being an employee of, and owning stock in, Pfizer. S.C.W. reports being an employee of, and owning stock in, Pfizer. S.L. reports being an employee of, and owning stock in, Pfizer. T.U. reports being an employee of, and owning stock in, Pfizer. K.D.W. reports being an employee of, and owning stock in, Pfizer. P.K.P. has nothing to disclose. No other potential conflict of interest relevant to this article was reported.